Serious adverse events in academic critical care research

descriptionPublicationkeyboard_double_arrow_right Article 22 Apr 2008 English Publisher:CMA Joule Inc.Journal:Canadian Medical Association Journal, volume 178, pages 1,181-1,184 (issn: 0820-3946, eissn: 1488-2329,

Copyright policy )Funded by:CIHR | unidentified

Authors: Deborah, Cook; François, Lauzier; Marcelo G, Rocha; Mary Jane, Sayles; Simon, Finfer;

doi: 10.1503/cmaj.071366

pmid: 18427095

pmc: PMC2292790

Serious adverse events in academic critical care research

- Summary
- Subjects
- Metrics

Abstract

Although it might be ideal to have a single system for defining and reporting serious adverse events that would be applicable to both academic trials investigating established drugs and industry-sponsored trials of novel pharmaceutical agents, such a system would be unlikely to satisfy all

Related Organizations

University of Sydney
Australia
McMaster University
Canada

Keywords

Clinical Trials as Topic, Intensive Care Units, Critical Care, Critical Illness, Adverse Drug Reaction Reporting Systems, Humans, Clinical Trials Data Monitoring Committees, Ethics Committees, Research

Impact byBIP!

	selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	104
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Top 1%
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Top 10%
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Top 10%